局部晚期宫颈癌图像引导自适应近距离放疗后晚期泌尿系统并发症风险:膀胱剂量-体积参数优化
本研究纳入2004至2015年接受放化疗联合脉冲剂量率近距离放疗的局部晚期宫颈癌患者297例,分析全膀胱及膀胱三角剂量-体积参数与晚期泌尿毒性的相关性。中位随访4.9年,无局部复发患者251例,3年和5年≥2级泌尿毒性累积发生率分别为25.4%和32.1%。建议膀胱D2cm3≤80 GyEQD2以降低严重泌尿并发症风险。
要点
- 膀胱D2cm3>80 GyEQD2、BICRU剂量>65 GyEQD2及三角D50%>60 GyEQD2均增加≥3级毒性风险。
- 建议膀胱D2cm3≤80 GyEQD2以将严重泌尿并发症风险控制在<15%。
核心结论
- 膀胱D2cm3≤80 GyEQD2应作为推荐约束以最小化严重泌尿并发症风险(<15%)。
- 膀胱三角剂量对严重晚期泌尿毒性也具有预测价值。
- 上述约束需在多中心前瞻性研究中进一步确认。
研究设计与样本
- 回顾性分析2004至2015年接受放化疗联合脉冲剂量率近距离放疗的局部晚期宫颈癌患者297例。
- 将全膀胱及膀胱三角累积剂量-体积参数转换为2 Gy分次等效剂量(EQD2,α/β=3 Gy)。
- 在无局部复发患者(n=251)中分析剂量-体积参数及临床因素与毒性的预测关系。
- 中位随访4.9年(95%CI 4.5-5.3年)。
主要发现
- 无局部复发患者3年和5年≥2级泌尿毒性Kaplan-Meier估计率分别为25.4%和32.1%。
- 膀胱D2cm3、BICRU剂量及三角剂量-体积参数与≥2级毒性相关。
关键数值与推荐
- 膀胱D2cm3≤80 GyEQD2为推荐约束,以降低严重泌尿并发症风险至<15%。
临床怎么用
- 在局部晚期宫颈癌图像引导自适应近距离放疗计划中,应将膀胱D2cm3控制在≤80 GyEQD2。
- 同时关注膀胱三角D50%,尤其在膀胱D2cm3≤80 GyEQD2时,三角D50%>60 GyEQD2仍与≥2级毒性显著相关。
- BICRU剂量>65 GyEQD2与≥3级毒性风险升高相关,计划评估时可参考该参数。
局限性
- 本研究为回顾性分析,结论需多中心前瞻性研究进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study correlations between dose-volume parameters of the whole bladder and bladder trigone and late urinary toxicity in locally advanced cervical cancer patients treated with pulsed-dose-rate brachytherapy. METHODS AND MATERIALS: Patients with locally advanced cervical cancer treated with chemoradiation therapy and pulsed-dose-rate brachytherapy from 2004 to 2015 were included. Cumulative dose-volume parameters of the whole bladder and bladder trigone were converted into 2-Gy/fraction equivalents (EQD2, with α/β = 3 Gy); these parameters, as well as clinical factors, were analyzed as predictors of toxicity in patients without local relapse. RESULTS: A total of 297 patients fulfilled the inclusion criteria. The median follow-up period was 4.9 years (95% confidence interval 4.5-5.3 years). In patients without local relapse (n = 251), the Kaplan-Meier estimated grade 2 or higher urinary toxicity rates at 3 years and 5 years were 25.4% and 32.1%, respectively. Minimal dose to the most exposed 2 cm3 of the whole bladder [Formula: see text] , bladder International Commission on Radiation Units & Measurements (ICRU) (BICRU) dose, and trigone dose-volume parameters correlated with grade 2 or higher toxicity. At 3 years, the cumulative incidence of grade 2 or higher complications was 22.8% (standard error, 2.9%) for bladder [Formula: see text] < 80 GyEQD2 versus 61.8% (standard error, 12.7%) for [Formula: see text] ≥ 80 GyEQD2 (P = .001). In the subgroup of patients with bladder [Formula: see text] ≤ 80 GyEQD2, a trigone dose delivered to 50% of the volume (D50%) > 60 GyEQD2 was significant for grade 2 or higher toxicity (P = .027). The probability of grade 3 or higher toxicities increased with bladder [Formula: see text] > 80 GyEQD2 (16.7% vs 1.6%; hazard ratio [HR], 5.77; P = .039), BICRU dose > 65 GyEQD2 (4.9% vs 1.3%; HR, 6.36; P = .018), and trigone D50% > 60 GyEQD2 (3.1% vs 1.2%; HR, 6.29; P = .028). Pearson correlation coefficients showed a moderate correlation between bladder [Formula: see text] , BICRU dose, and bladder trigone D50% (P < .0001). CONCLUSIONS: These data suggest that [Formula: see text] ≤ 80 GyEQD2 should be advised for minimizing the risk of severe urinary complications (<15%). Bladder trigone dose was also predictive of severe late urinary toxicity. These constraints need further confirmation in a multicenter prospective setting.
引用
- Manea E, Escande A, Bockel S, et al. Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559282. doi:10.1016/j.ijrobp.2018.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。